Abstract. The precise pathogenic mechanism of platelet destruction in immune thrombocytopenias is not known, although many investigators have found that platelet-associated IgG is increased in these diseases. We report here the differentiation between specific binding of anti-platelet antibody, associated with platelet destruction, and the ubiquitous presence of nonspecific, platelet-associated IgG. Using an electrophoretic separation and antibody overlay technique, we have identified a specific membrane protein that bears target platelet antigens in immune thrombocytopenias.
When posttransfusion purpura serum was studied, antibody binding to the PIl" antigen on glycoprotein
I11a was readily distinguished from the nonspecific binding of immunoglobulin to a protein of 200,000 mol wt.
After reduction of disulfide bonds, the PIl" antigenicity was not observed, and IgG bound nonspecifically to a protein band with an apparent molecular weight of 45,000.
We have also identified anti-platelet antibodies in patients with idiopathic thrombocytopenic purpura and determined their antigenic specificity. Antibodies which bind to a 100,000-mol wt protein were found in nine of thirteen patients with chronic disease. The antigens in three of these cases were studied in detail by using both reduced and nonreduced control and Glanzmann's This paper was presented in abstract form in 1982. Blood. 60(5)Suppl.
1:1848.
Received for publication 26 August 1983 and in revised form 24 July 1984. thrombasthenic platelets. Target antigens were localized to glycoprotein lIla, but are different from plAI. The immune thrombocytopenic purpura antigenic system is clearly distinguished from nonspecific platelet-associated IgG. Sera from eight children with acute idiopathic thrombocytopenic purpura were also studied. In all cases, the nonspecific IgG binding to the 200,000-mol wt protein was observed. However, we were unable to demonstrate antibody binding to glycoprotein IIIa, which suggested that the acute childhood form of this disease may have a different pathogenic mechanism than that of the autoimmune chronic cases.
Introduction
Antibody mediated platelet destruction is a common cause of thrombocytopenia and clinical bleeding (1-3); however, the precise mechanism of platelet destruction is not known. More than 30 yr ago Harrington et al. (4) reported that the globulin fraction of plasma from patients with immune thrombocytopenic purpura (ITP)' contained a factor responsible for platelet destruction. Possible agents for such opsonization of platelets might include true autoantibodies, immune complexes, and antibodies crossreactive with viral and platelet antigens.
While an increased amount of immunoglobulin is often found associated with platelets in these syndromes (5) (6) (7) (8) , its role in platelet destruction is unclear. Recently, the significance of the increase in platelet-associated IgG (PAIgG) found in immune-mediated platelet destruction has been questioned (9, 10) . There is great variation in levels of PAIgG among patients with ITP, but poor correlation between PAIgG levels and clinical course of the disease (1, 2) . Current techniques for quantitating PAIgG do not distinguish between antibody directed against a specific platelet antigen and IgG that is nonspecifically adsorbed onto the platelet surface. There are reports documenting the presence of a receptor for the Fc portion of IgG on the platelet surface which binds some subclasses of IgG without regard to their antigen specificity (1 1, 12) . Binding of aggregated IgG or immune complexes to this receptor can be inhibited by normal plasma concentrations of monomeric IgG (13) . Therefore, the physiologic significance of this receptor has not been established. We tested the hypothesis that true autoantibodies occur in some immune thrombocytopenias and identified platelet proteins containing the target antigens for these anti-platelet antibodies.
The target antigen implicated in posttransfusion purpura and in most cases of neonatal alloimmune thrombocytopenia is P1A', which has been localized to glycoprotein Illa (GPIIIa) (14, 15) . However, the target antigens for antibodies in ITP patients are not well characterized. It has recently been reported that immunoglobulins from patients with ITP react with normal platelets but not with platelets from patients with Glanzmann's thrombasthenia (16). Thrombasthenic platelets are deficient in glycoproteins IIb and IIIa (17, 18) , so either or both of these major membrane proteins could bear important target antigens for destructive antibodies. Human hybridoma monoclonal anti-platelet antibodies have been produced from the fusion of a plasma cell line with lymphocytes isolated from a patient with ITP (19) for 30 min at room temperature. 1.2 X 107 labeled platelets in fresh plasma were incubated with 0.05 ml of anti-PI" antiserum, incubated for 2 h at 370C, and sedimented. 5"Cr release was determined by counting the radioactivity of the supernatant. The P1"' specificity of the antiserum was assessed by comparison of results of typing platelets from a large number of individuals using defined anti-PI' antibody that was kindly supplied by Dr. Richard Aster, Blood Center of Southeastern Wisconsin, Milwaukee, WI.
Lactoperoxidase catalyzed 125I labeling ofplatelets. Platelets from 20 ml of blood in acid citrate dextrose were washed twice in 10 mM Tris-HCI, 0.15 M NaCI, 2 mM EDTA, pH 7.8, and resuspended at a density of 1.5 X 109 platelets/ml. To each milliliter of platelet suspension, 250 MCi ['25I]NaI (17 Immune staining-'25I antiglobulin technique. Remaining nonspecific protein binding sites on the nitrocellulose paper were blocked by incubation with 10% (wt/vol) BSA and 0.5% bovine gamma globulin in PBS (BSA/BGG) for 1 h at 370C. The blot was then incubated for 1 h at 250C with 25 Ml of the serum to be tested and diluted into 8 ml BSA/BGG. Unbound IgG was removed by washing 10 times with 50 ml of cold PBS in a Petri dish with gentle agitation. Localization of bound immunoglobulin was accomplished by incubation with affinity purified '25l-labeled goat anti-human IgG (Litton Bionetics, Kensington, MD) for 1 h at 250C or overnight at 4VC (106 cpm/ml). After washing 10 times with 50 ml PBS, the blot was exposed to X-Omat AR x-ray film (Eastman Kodak Co., Rochester, NY) for 4-24 h at -700C.
Adsorption and ether elution of ITP antibodies from platelets.
Platelets prepared as described above were incubated with test serum in a ratio of 0.3 ml of platelet suspension (109 cells/ml in 0.2% BSA, 2 mM EDTA in PBS) to 0.3 ml of serum and incubated at 37°C for 30 min. The platelets were sedimented in a Beckman microfuge for 5 min, the supernatant was discarded, and the platelets were washed three times with 1 ml of 0.2% BSA, 2 mM EDTA in PBS, and resuspended in 0.3 ml of the same buffer. The elution technique used is a modification of the method of von dem Borne (31). Diethyl ether was added to a total volume of 1.0 ml and the suspension was vortexed vigorously for 2 min and then incubated for 30 min in closed tubes at 570C in a hood. After centrifugation for 5 min in the microfuge, the upper layers of ether and stroma were aspirated, leaving the aqueous eluate. The eluate, -0.3 ml, was diluted to 8 ml with BSA/BGG and used to stain the nitrocellulose transfers.
Immune staining-peroxidase technique. Nitrocellulose strips containing a single lane of platelet proteins were incubated first with 1.5% goat serum in PBS for 1 h to saturate protein binding sites and then with a 1:50 dilution of ITP serum in PBS with 1% BSA (PBS/l% BSA) for 1 h. The strips were washed 3-5 times for 5 min with 2.5 ml of PBS/1% BSA or PBS between subsequent incubation steps. A 1:200 dilution of biotinylated affinity purified goat anti-human IgG (Vector Laboratories, Burlingame, CA) in PBS/1% BSA was added for 15 min.
After exposure for 30 min to a 1% solution of avidin and biotinylated horseradish peroxidase (Vector Laboratories) in PBS containing 0.1% Tween 20 detergent, 25 ml of 0.02% chloronaphthol and 0.006% hydrogen peroxide in PBS were added. Purple bands developed within 2 min. All solutions were prepared fresh each day; azide was not added, since it inhibits the peroxidase reaction.
Results
Identification ofthe PI"A antigen-bearing protein. Our (Fig. 1 C) or when the target platelets were from a patient with Glanzmann's thrombasthenia (Fig. 1 D) .
This patient has a documented absence of glycoproteins I1b and lIla (23, 24) . Reduction of disulfide bonds in the normal platelet sample with 1.0% 2-mercaptoethanol at 1000C for 5 min also completely eliminated antibody binding to the 100,000-mol wt band. These findings were in accord with reports localizing the PIAl antigen to glycoprotein lila (14, 15) , and established that the antigenicity of P1AI could survive the solubilization, separation, and transfer processes.
"Nonspecific" binding of immunoglobin to platelets. When the nonreduced, electrophoretically separated platelet proteins were incubated with either control or anti-PlAl serum, additional bound immunoglobulin was identified at 200,000 mol wt (Fig.  1, A, C, and D) . This band was also observed if the serum incubation was omitted and the platelet proteins were incubated directly with 1251I goat anti-human IgG (Fig. 2, A figure. Note the 100,000-mol wt band which co-migrates with GPIIIa.
-150,000 mol wt could be accentuated by overexposure of the autoradiograms. The intensity of this band varied with different platelet preparations. It was very strong if the platelets were not gel filtered. When platelet proteins were reduced with 2-mercaptoethanol, the 200,000-mol wt band disappeared and bands appeared at molecular weights of 50,000 and 25,000 (Fig. 2 C) . However, if the separated, reduced platelet proteins were first incubated with heat-aggregated serum, additional IgG bound to a 45,000-mol wt band (Fig. 2 D) . Furthermore, exposure of the electrophoretically separated platelet proteins to heat aggregated 125I-labeled human IgG resulted in direct binding of radioactivity to the 200,000-mol wt band of the nonreduced platelet proteins and to the 45,000-mol wt band of reduced proteins (results not shown).
Binding of ITP antibodies to platelet membrane proteins. Although sera from patients with ITP appear to contain opsonic activity against platelets, indirect antibody tests are frequently negative (2) . To concentrate the anti-platelet immunoglobulins, these sera were initially incubated with normal platelets. After washing to remove plasma proteins, plateletbound antibody was eluted with ether as detailed in Methods. Because this treatment is harsh, we found that recovery of antibody activity was unpredictable. Therefore, we developed and used the more sensitive peroxidase technique for antigen identification, which is detailed in Methods.
Sera from 13 patients with chronic ITP (see Table I ) were studied using the adsorption and elution technique. In nine cases, a specific band was found at 100,000 mol wt, comigrating with glycoprotein IIIa (e.g., Fig. 3 B) . In the four other patients with chronic ITP, only the nonspecific 200,000-mol wt band was seen. When target platelet proteins from a patient with type I Glanzmann's thrombasthenia were used to test three of these sera, no antibody bound to the 100,000-mol wt protein (Fig. 3 D) , which confirmed its identification as glycoprotein IIIa. When disulfide bonds were reduced in the target control platelet proteins, the antigenic band was noted at 110,000 mol wt. This increase in apparent molecular weight with disulfide reduction is characteristic of GPIIIa (32) . In order to test whether the antiplatelet antibodies in ITP sera were directed against the PIl" antigen, three of these ITP sera were tested against p1A' negative platelets. The 100,000-mol wt band was still observed (e.g., Fig. 3 E) . We also studied sera from eight children with acute ITP of childhood. AntiGPIIIa antibodies were not demonstrated in any of these patients. Detection of platelet-directed antibody in the serum of a patient with ITP does not assure that it is an autoantibody. Patients who have been transfused or pregnant may have platelet specific alloantibodies or isoantibodies. Six of our nine patients with specific platelet directed IgG had been transfused; none had been pregnant. We directly demonstrated in two cases that the anti-GPIIIa IgG was truly an autoantibody. In one case, IgG eluted from patient platelets was shown to bind to the 100,000-mol wt band of control platelets. In another case, the patient's own platelet proteins were used as the target for immune staining. IgG in the same patient's serum bound to the 100,000-mol wt band (results not shown).
Discussion
While increased platelet bound IgG has a well documented association with immune thrombocytopenias, the precise mechanism for platelet opsonization and destruction has not been elucidated. We report here the direct demonstration of anti-platelet autoantibodies in a subset of patients with chronic ITP. Since we have been able to differentiate antiplatelet IgG from nonspecific platelet-associated IgG, we were also able to identify the platelet protein bearing target antigens in immune thrombocytopenias.
Platelet glycoprotein Ila was shown to contain the plAl antigen, confirming previous reports (14, 15) . Using anti-PlA' posttransfusion purpura serum, antibody binding was demonstrated to an antigenic protein with an apparent molecular weight of 100,000, which disappeared after reduction with 2-mercaptoethanol. Indirect (12) . The precise nature of the receptor we observe is currently under investigation. In summary, we have identified antibody binding to platelet antigens on a 100,000-mol wt protein, GPIIIa, and we have separated this specific anti-platelet IgG binding from nonspecific immunoglobulin associated with normal platelets. The antiplatelet antibodies we observed in a subset of patients with chronic ITP also bound to GPIIIa. These anti-GPIIIa antibodies were not found in any of the acute ITP patients that were studied. If future prospective studies confirm this finding, demonstration of autoantibody could be used to identify a subset of patients who are destined to have chronic ITP at the time of presentation, and therefore improve decisions regarding patient management.
